Literature DB >> 17318625

Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue.

C Moro1, E Klimcakova, K Lolmède, M Berlan, M Lafontan, V Stich, A Bouloumié, J Galitzky, P Arner, D Langin.   

Abstract

AIMS/HYPOTHESIS: Increased adipose tissue secretion of adipokines and cytokines has been implicated in the chronic low-grade inflammation state and insulin resistance associated with obesity. We tested here whether the cardiovascular and metabolic hormone atrial natriuretic peptide (ANP) was able to modulate adipose tissue secretion of several adipokines (derived from adipocytes) and cytokines (derived from adipose tissue macrophages). SUBJECTS AND METHODS: We used protein array to measure the secretion of adipokines and cytokines after a 24-h culture of human subcutaneous adipose tissue pieces treated or not with a physiological concentration of ANP. The effect of ANP on protein secretion was also directly studied on isolated adipocytes and macrophages. Gene expression was measured by real-time RT-quantitative PCR.
RESULTS: ANP decreased the secretion of the pro-inflammatory cytokines IL-6 and TNF-alpha, of several chemokines, and of the adipokines leptin and retinol-binding protein-4 (RBP-4). The secretion of the anti-inflammatory molecules IL-10 and adiponectin remained unaffected. The cytokines were mainly expressed in macrophages that expressed all components of the ANP-dependent signalling pathway. The adipokines, leptin, adiponectin and RBP-4 were specifically expressed in mature adipocytes. ANP directly inhibited the secretion of IL-6 and monocyte chemoattractant protein-1 by macrophages. The inhibitory effects of ANP on leptin and growth-related oncogene-alpha secretions were not seen under selective hormone-sensitive lipase inhibition. CONCLUSIONS/
INTERPRETATION: We suggest that ANP, either by direct action on adipocytes and macrophages or through activation of adipocyte hormone-sensitive lipase, inhibits the secretion of factors involved in inflammation and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318625     DOI: 10.1007/s00125-007-0614-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  50 in total

1.  Microdetermination of long-chain fatty acids in plasma and tissues.

Authors:  V P DOLE; H MEINERTZ
Journal:  J Biol Chem       Date:  1960-09       Impact factor: 5.157

2.  Recombinant human growth-regulated oncogene-alpha induces T lymphocyte chemotaxis. A process regulated via IL-8 receptors by IFN-gamma, TNF-alpha, IL-4, IL-10, and IL-13.

Authors:  T Jinquan; J Frydenberg; N Mukaida; J Bonde; C G Larsen; K Matsushima; K Thestrup-Pedersen
Journal:  J Immunol       Date:  1995-12-01       Impact factor: 5.422

3.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.

Authors:  Timothy E Graham; Qin Yang; Matthias Blüher; Ann Hammarstedt; Theodore P Ciaraldi; Robert R Henry; Christopher J Wason; Andreas Oberbach; Per-Anders Jansson; Ulf Smith; Barbara B Kahn
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; G Howard; L Mykkänen; R P Tracy; S M Haffner
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

5.  A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha.

Authors:  Takayoshi Suganami; Junko Nishida; Yoshihiro Ogawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-08-25       Impact factor: 8.311

6.  Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase.

Authors:  Andrew L Carey; Gregory R Steinberg; S Lance Macaulay; Walter G Thomas; Anna G Holmes; Georg Ramm; Oja Prelovsek; Cordula Hohnen-Behrens; Matthew J Watt; David E James; Bruce E Kemp; Bente K Pedersen; Mark A Febbraio
Journal:  Diabetes       Date:  2006-10       Impact factor: 9.461

7.  Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors.

Authors:  Daniela Dietze-Schroeder; Henrike Sell; Mathias Uhlig; Marlis Koenen; Jürgen Eckel
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

8.  HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy.

Authors:  Yan Xu; Joseph Kulkosky; Edward Acheampong; Giuseppe Nunnari; Julie Sullivan; Roger J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-21       Impact factor: 11.205

9.  Impact of obesity on plasma natriuretic peptide levels.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

10.  Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adrenocortical steroids?

Authors:  Alexander Niessner; Sophie Ziegler; Jörg Slany; Elke Billensteiner; Wolfgang Woloszczuk; Georg Geyer
Journal:  Eur J Endocrinol       Date:  2003-12       Impact factor: 6.664

View more
  43 in total

1.  Regulation of retinol binding protein 4 production in primary human adipocytes by adiponectin, troglitazone and TNF-alpha.

Authors:  H Sell; J Eckel
Journal:  Diabetologia       Date:  2007-07-28       Impact factor: 10.122

2.  Genetics of new-onset diabetes after transplantation.

Authors:  Jennifer A McCaughan; Amy Jayne McKnight; Alexander P Maxwell
Journal:  J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 10.121

Review 3.  The paradox of low BNP levels in obesity.

Authors:  Aldo Clerico; Alberto Giannoni; Simona Vittorini; Michele Emdin
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

4.  Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?

Authors:  Rafael de la Espriella-Juan; Juan Sanchis; Antoni Bayés-Genís; Julio Núñez
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

Review 5.  Pharmacogenetics of posttransplant diabetes mellitus.

Authors:  P Lancia; T Adam de Beaumais; E Jacqz-Aigrain
Journal:  Pharmacogenomics J       Date:  2017-03-28       Impact factor: 3.550

6.  Inflammation and Circulating Natriuretic Peptide Levels.

Authors:  Hannah Fish-Trotter; Jane F Ferguson; Nirav Patel; Pankaj Arora; Norrina B Allen; Katherine N Bachmann; Lori B Daniels; Muredach P Reilly; Joao A C Lima; Thomas J Wang; Deepak K Gupta
Journal:  Circ Heart Fail       Date:  2020-06-08       Impact factor: 8.790

7.  Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study.

Authors:  Martin Magnusson; Amra Jujic; Bo Hedblad; Gunnar Engström; Margaretha Persson; Joachim Struck; Nils G Morgenthaler; Peter Nilsson; Christopher Newton-Cheh; Thomas J Wang; Olle Melander
Journal:  J Clin Endocrinol Metab       Date:  2011-11-23       Impact factor: 5.958

Review 8.  Cardiomyokines from the heart.

Authors:  Ayano Chiba; Haruko Watanabe-Takano; Takahiro Miyazaki; Naoki Mochizuki
Journal:  Cell Mol Life Sci       Date:  2017-12-13       Impact factor: 9.261

9.  Influence of regular physical activity and caloric restriction on β-adrenergic and natriuretic peptide receptor expression in retroperitoneal adipose tissue of OLETF rats.

Authors:  Nathan T Jenkins; Jaume Padilla; R Scott Rector; M Harold Laughlin
Journal:  Exp Physiol       Date:  2013-07-05       Impact factor: 2.969

10.  Role of microtubules in attenuation of PepG-induced vascular endothelial dysfunction by atrial natriuretic peptide.

Authors:  Yufeng Tian; Isa Mambetsariev; Nicolene Sarich; Fanyong Meng; Anna A Birukova
Journal:  Biochim Biophys Acta       Date:  2014-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.